High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals.
Acute SARS-CoV-2 infections are not always diagnosed; hence an unknown proportion of all infections are not documented. SARS-CoV-2 can induce spike and nucleocapsid protein specific IgG antibodies, which can be detected in seroprevalence studies to identify a previous infection. However, with the in...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLOS Global Public Health |
| Online Access: | https://doi.org/10.1371/journal.pgph.0003300 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832539958644047872 |
|---|---|
| author | Kim Blom Ilias Galanis Philip Bacchus Klara Sondén Ioana Bujila Tatiana Efimova Fredrik Garli Mikael Mansjö Elin Movert Aleksandra Pettke Marie Rapp Maike Sperk Sandra Söderholm Karin Valentin Asin Sarah Zanetti Magnus Gisslén Andreas Bråve Ramona Groenheit Jonas Klingström |
| author_facet | Kim Blom Ilias Galanis Philip Bacchus Klara Sondén Ioana Bujila Tatiana Efimova Fredrik Garli Mikael Mansjö Elin Movert Aleksandra Pettke Marie Rapp Maike Sperk Sandra Söderholm Karin Valentin Asin Sarah Zanetti Magnus Gisslén Andreas Bråve Ramona Groenheit Jonas Klingström |
| author_sort | Kim Blom |
| collection | DOAJ |
| description | Acute SARS-CoV-2 infections are not always diagnosed; hence an unknown proportion of all infections are not documented. SARS-CoV-2 can induce spike and nucleocapsid protein specific IgG antibodies, which can be detected in seroprevalence studies to identify a previous infection. However, with the introduction of vaccines containing the spike protein it is no longer possible to use spike-IgG as a marker of infection. In many countries marketed vaccines do not include the nucleocapsid protein, allowing the use of nucleocapsid-specific IgG (N-IgG) as a specific marker for previous infection. Importantly however, not all SARS-CoV-2-infected individuals develop detectable N-IgG responses and there are reports of waning of N-IgG titers in previously infected individuals, complicating the use of N-IgG in seroprevalence studies. Here, our aim was to investigate N-IgG as a marker for previous infection. To this end we analyzed a well characterized cohort (n = 2,583; sampled in March, 2022), including 612 participants with a previously diagnosed and documented SARS-CoV-2-infection. We show that 75% (460/612) of the confirmed SARS-CoV-2-infected participants were N-IgG positive, and that the frequency of seropositivity was stable for at least 105 weeks after the latest documented SARS-CoV-2-infection. Among participants with no documented SARS-CoV-2-infection, 32.6% (642/1971) were N-IgG-positive, suggesting a previous infection. Assuming similar frequency of N-IgG-seronegative cases in previously diagnosed and undiagnosed individuals we further estimate that 214 of the 1329 undiagnosed and N-IgG-negative cases had been previously infected, indicating a total infection rate of 56.8% (1,468/2,583), clearly higher than the documented 23.7% rate of infection, in this cohort. In conclusion, our results suggest that while N-IgG is a good marker of previous SARS-CoV-2-infection the large proportion of previously infected N-IgG-negative individuals introduces a risk for underestimations of total level of previously infected individuals in a population. Accounting for this dark number of undiagnosable cases can provide better estimates of total level of infected individuals in a population. |
| format | Article |
| id | doaj-art-377d10c74cfe4185a7d2e0f70683a55f |
| institution | Kabale University |
| issn | 2767-3375 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLOS Global Public Health |
| spelling | doaj-art-377d10c74cfe4185a7d2e0f70683a55f2025-02-05T05:50:25ZengPublic Library of Science (PLoS)PLOS Global Public Health2767-33752025-01-0151e000330010.1371/journal.pgph.0003300High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals.Kim BlomIlias GalanisPhilip BacchusKlara SondénIoana BujilaTatiana EfimovaFredrik GarliMikael MansjöElin MovertAleksandra PettkeMarie RappMaike SperkSandra SöderholmKarin Valentin AsinSarah ZanettiMagnus GisslénAndreas BråveRamona GroenheitJonas KlingströmAcute SARS-CoV-2 infections are not always diagnosed; hence an unknown proportion of all infections are not documented. SARS-CoV-2 can induce spike and nucleocapsid protein specific IgG antibodies, which can be detected in seroprevalence studies to identify a previous infection. However, with the introduction of vaccines containing the spike protein it is no longer possible to use spike-IgG as a marker of infection. In many countries marketed vaccines do not include the nucleocapsid protein, allowing the use of nucleocapsid-specific IgG (N-IgG) as a specific marker for previous infection. Importantly however, not all SARS-CoV-2-infected individuals develop detectable N-IgG responses and there are reports of waning of N-IgG titers in previously infected individuals, complicating the use of N-IgG in seroprevalence studies. Here, our aim was to investigate N-IgG as a marker for previous infection. To this end we analyzed a well characterized cohort (n = 2,583; sampled in March, 2022), including 612 participants with a previously diagnosed and documented SARS-CoV-2-infection. We show that 75% (460/612) of the confirmed SARS-CoV-2-infected participants were N-IgG positive, and that the frequency of seropositivity was stable for at least 105 weeks after the latest documented SARS-CoV-2-infection. Among participants with no documented SARS-CoV-2-infection, 32.6% (642/1971) were N-IgG-positive, suggesting a previous infection. Assuming similar frequency of N-IgG-seronegative cases in previously diagnosed and undiagnosed individuals we further estimate that 214 of the 1329 undiagnosed and N-IgG-negative cases had been previously infected, indicating a total infection rate of 56.8% (1,468/2,583), clearly higher than the documented 23.7% rate of infection, in this cohort. In conclusion, our results suggest that while N-IgG is a good marker of previous SARS-CoV-2-infection the large proportion of previously infected N-IgG-negative individuals introduces a risk for underestimations of total level of previously infected individuals in a population. Accounting for this dark number of undiagnosable cases can provide better estimates of total level of infected individuals in a population.https://doi.org/10.1371/journal.pgph.0003300 |
| spellingShingle | Kim Blom Ilias Galanis Philip Bacchus Klara Sondén Ioana Bujila Tatiana Efimova Fredrik Garli Mikael Mansjö Elin Movert Aleksandra Pettke Marie Rapp Maike Sperk Sandra Söderholm Karin Valentin Asin Sarah Zanetti Magnus Gisslén Andreas Bråve Ramona Groenheit Jonas Klingström High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals. PLOS Global Public Health |
| title | High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals. |
| title_full | High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals. |
| title_fullStr | High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals. |
| title_full_unstemmed | High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals. |
| title_short | High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals. |
| title_sort | high prevalence of undocumented sars cov 2 infections revealed by analysis of nucleocapsid specific igg responses in diagnosed and undiagnosed individuals |
| url | https://doi.org/10.1371/journal.pgph.0003300 |
| work_keys_str_mv | AT kimblom highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT iliasgalanis highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT philipbacchus highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT klarasonden highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT ioanabujila highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT tatianaefimova highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT fredrikgarli highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT mikaelmansjo highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT elinmovert highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT aleksandrapettke highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT marierapp highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT maikesperk highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT sandrasoderholm highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT karinvalentinasin highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT sarahzanetti highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT magnusgisslen highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT andreasbrave highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT ramonagroenheit highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals AT jonasklingstrom highprevalenceofundocumentedsarscov2infectionsrevealedbyanalysisofnucleocapsidspecificiggresponsesindiagnosedandundiagnosedindividuals |